1 Trending: Corporate Media Downplay Another Apparent Assassination Attempt Against Trump

2 Trending: ‘So Proud To Be Americans’: U.S. Men’s Hockey Team Defeats Canada In Overtime Battle For Olympic Gold

3 Trending: Colorado Bill Would Take Kids Away From Parents Who Refuse To Trans Them

4 Trending: Fortune 500’s DEI Retreat Shows The Corporate Social Credit System Is Collapsing

Despite Promise To Be Pro-Life ‘Ally,’ Trump Admin Won’t Regulate Abortion Drug Endangering Women

The FDA appears to be slow-walking its mifepristone review, frustrating Trump allies in both Congress and pro-life states.

Share Article on Facebook

Share Article on Twitter

Share Article on Truth Social

Share Article via Email

It is well established that mifepristone, the popular abortion drug, is deadly to unborn babies and dangerous to women — especially those who take it without medical oversight. Confidence that the Trump administration will do anything to curb the harms wrought by the Biden administration’s radical expansion of mail-order abortion drugs, however, is dwindling.

New polling from Cygnal suggests that 32 percent of Republican voters are unmotivated to show up for the midterms “if Republican leaders weaken or abandon pro-life policies.” Trump, who fears impeachment if the GOP loses control of Congress come November, can’t afford to be shunned by the pro-life base that played a pivotal role in electing and reelecting him. Yet, he has deliberately avoided addressing mifepristone and the Biden-era mail-order scheme that has contributed to the deadly drug’s popularity.

Trump’s silence is unsurprising given his history of blaming pro-life issues for Republicans’ political losses. What is surprising to the pro-life organizations and GOP legislators is that their demands that the U.S. Food and Drug Administration at least restore the mifepristone safeguards present during the first Trump administration have yet to manifest in any measurable action.

Pro-lifers believe this stalling is deliberate. SBA List Pro-Life America and Live Action’s Lila Rose used an anonymously-sourced article claiming the FDA head was “Slow Walking a Long-Awaited Abortion Pill Safety Study” to call for FDA Commissioner Marty Makary’s firing.

Sen. Josh Hawley, R-Mo., told The Federalist in a phone call that he also believes, after conversations with Makary, that the FDA’s “safety study thing is just a dead end.”

“Women are being lied to, babies are being killed, and we need to do something about it. I’ve concluded that the safety study, which the FDA promised they would initiate a year ago, it just doesn’t seem to be going anywhere to me,” Hawley said.

Both U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and Makary pledged throughout 2025 to review the data suggesting the popular abortion pill drug regimen linked to hemorrhage, “fast, weak pulse,” “trouble breathing,” diarrhea, dizziness, headache, vomiting, and “pain” across the back, arms, neck, and abdomen.

The real push for the FDA to act didn’t heat up after the Ethics and Public Policy Center’s April 2025 examination of private medical insurance data determined that more than one in 10 women who take mifepristone suffer a serious adverse event such as........

© The Federalist